Cannabis and cancer;Cannabis et cancer

Bulletin du Cancer

Volumn 93, Issue 2, 2006, Pages 163-170

  Vignot, Stéphane ^a   Besse, Benjamin ^a   De La Motte Rouge, Thibault ^a   Massard, Christophe ^a   Spano, Jean Philippe ^a   Karila, Laurent ^a  

^a Association d'Études et de Recherche des Internes en Oncologie   (France)

Author keywords

Cancer; Cannabinoide; Cannabis; Tetrahydrocannabinol

Indexed keywords

ANALGESIC AGENT; APPETITE STIMULANT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PAIN; CARCINOGENIC ACTIVITY; COLON CANCER; GLIOBLASTOMA; HUMAN; LUNG CANCER; LYMPHOMA; PROSTATE CANCER; REVIEW; THYROID CANCER; UTERUS CANCER;

CANNABINOIDS; HUMANS; NEOPLASMS;

EID: 33645239509     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev, 2002.
2. Choquet M, Beck F, Hassler C, Spilka S, Morin D, Legleye S. La substances psychoactives chez les collégiens et lycéens: consommations en 2003 et évolutions depuis dix ans. Tendances. Inserm & OFDT, 2004.
3. Grant S, Contoreggi C, London ED. Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia 2000; 38: 1180-7.
4. Hall W, MacPhee D. Cannabis use and cancer. Addiction 2002; 97: 243-7.
5. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996; 30: 109-17.
6. MacPhee D. Effects of marijuana on cell nuclei: a review of the literature relating to the genotoxicity of cannabis. In The health effects of cannabis. Toronto: Centre for Addiction and Mental Health, 1999.
7. Leuchtenberger C. Effects of marijuana (cannabis) smoke on cellular biochemistry of in vitro test systems. In Cannabis and health hazards. Toronto: Addiction Research Foundation, 1983.
8. Wu TC, Tashkin DP, Djahed B, Rose JB. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988; 318: 347-51.
9. Fligiel SE, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. Chest 1997; 112: 319-26
10. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst 1998; 90: 1198-205.
11. Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 1997; 156: 1606-13.
12. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000; 165: 373-80.
13. Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta(9)-tetrahydrocannabinol. Am J Res Cell Mol Biol 2001; 24: 339-44.
14. Sidney S, Quesenberry CP, Friedman GD, Tekawa IS. Marijuana use and cancer incidence (California, United States). Cancer Causes Control 1997; 8: 722-8.
15. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999; 8: 1071-8.
16. Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya S. An analysis of risk factors tor oral cancer in young people: a case-control study. Oral Oncol 2004; 40: 304-13.
17. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975; 55: 597-602.
18. Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 2005; 105: 1214-21.
19. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100: 627-34.
20. Sanchez C, De Ceballos ML, Del Pulgar TG, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB (2) cannabinoid receptor. Cancer Res 2001; 61: 5784-9.
21. Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436: 6-10.
22. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313-9.
23. Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994; 55: 107-15.
24. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 1995; 369: 177-82.
25. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003; 17: 1771-3.
26. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2005; 111: 43-50.
27. Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17: 529-31.
28. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004; 64: 1943-50.
29. Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Guzman M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 2004; 47: 315-23.
30. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64: 5617-23.
31. Collège des pharmaciens de la province de Barcelone. www.farmaceuticonline.com (en espagnol), 2004.
32. De Jong FA, Engels FK, Mathijssen RH, van Zuylen L, Verweij J, Peters RP, et al. Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol 2005; 23: 2886-91.
33. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-48.
34. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95: 127-35.
35. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB (1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415: R5-7.
36. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999; 96: 12198-203.
37. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-12.
38. Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004; 109: 124-31.
39. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neural 2003; 2: 291-8.
40. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395: 381-3.
41. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J 2001; 323: 13-6.
42. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757-62.
43. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
44. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 2004; 329: 253.
45. Erkens JA, Janse AF, Herings RM. Limited use of medicinal cannabis but for labeled indications after legalization. Pharmacoepidemiol Drug Saf, 2005.
46. Voth EA, Schwartz RH. Medicinal applications of delta-9- tetrahydrocannabinol and marijuana. Ann Intern Med 1997; 126: 791-8.
47. Lapey JD. Medicinal uses of marijuana. Ann Intern Med 1997; 127: 1134-5.
48. Bayer R. Medicinal uses of marijuana. Ann Intern Med 1997; 127: 1134; (author reply 1135).
49. O'Connell TJ. Medicinal uses of marijuana. Ann Intern Med 1997; 127: 1134; (author reply 1135).
50. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J 2001; 323: 16-21.
51. ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2001; 12: 1059-60.
52. Fédération nationale des centres de lutte contre le cancer. Standards options et recommandations pour l'utilisation des médicaments anti-émétiques en cancérologie. Montrouge: John Libbey Eurotext, 1997.
53. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979; 91: 819-24.
54. Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979; 91: 825-30.
55. Tchekmedyian NS, Zahyna D, Halpert C, Heber D. Clinical aspects of nutrition in advanced cancer. Oncology 1992; 49(Suppl 2): 3-7.
56. Desport JC, Blanc-Vincent MP, Gory-Delabaere G, Bachmann P, Beal J, Benamouzig R, et al. Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCO)]. Bull Cancer 2000; 87: 315-28.
57. Williams CM, Kirkham TC. Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 2002; 76: 241-50.
58. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-5.
59. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-73.